RDY Stock Overview
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
RDY passed our risk checks.
Dr. Reddy's Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹71.31 |
| 52 Week High | ₹77.72 |
| 52 Week Low | ₹53.12 |
| Beta | 0.34 |
| 1 Month Change | -5.54% |
| 3 Month Change | 4.64% |
| 1 Year Change | 18.28% |
| 3 Year Change | 5.12% |
| 5 Year Change | 74.57% |
| Change since IPO | 1,312.08% |
Recent News & Updates
Recent updates
Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements
Nov 29Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook
Oct 27Dr. Reddy's: Growth Supported By New Labels, Profitability
Aug 23Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy
Jun 07Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy
Feb 16Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed
Jan 20Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue
Nov 07Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M
Jul 28Dr. Reddy's launches generic drugs for allergies in US
Jul 22Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases
Jul 05Dr. Reddy's in talks to bring single-dose Sputnik Light vaccine in India
May 31Shareholder Returns
| RDY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.8% | -2.2% | -3.7% |
| 1Y | 18.3% | 11.6% | 20.5% |
Return vs Industry: RDY exceeded the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: RDY underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| RDY volatility | |
|---|---|
| RDY Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RDY has not had significant price volatility in the past 3 months.
Volatility Over Time: RDY's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 25,863 | Erez Israeli | www.drreddys.com |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.
Dr. Reddy's Laboratories Limited Fundamentals Summary
| RDY fundamental statistics | |
|---|---|
| Market cap | US$12.05b |
| Earnings (TTM) | US$624.05m |
| Revenue (TTM) | US$3.24b |
19.3x
P/E Ratio3.7x
P/S RatioIs RDY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDY income statement (TTM) | |
|---|---|
| Revenue | ₹271.30b |
| Cost of Revenue | ₹113.18b |
| Gross Profit | ₹158.12b |
| Other Expenses | ₹105.92b |
| Earnings | ₹52.21b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 313.51 |
| Gross Margin | 58.28% |
| Net Profit Margin | 19.24% |
| Debt/Equity Ratio | 6.0% |
How did RDY perform over the long term?
See historical performance and comparison